E-LIB Suche - Ergebnisse für: Antoniotti, C.

1

53P Trifluridine/tipiracil plus capecitabine and bevacizuma..:

Ciracì, P. ; Conca, V. ; Moretto, R....
Annals of Oncology. 35 (2024) - p. S25-S26 , 2024

Link: https://doi.org/10.1016/..

2

63P FOLFOXIRI/bevacizumab (bev) versus doublets/bev as init..:

Marmorino, F. ; Antoniotti, C. ; Meinert, F.M....
Annals of Oncology. 35 (2024) - p. S30 , 2024

Link: https://doi.org/10.1016/..

3

158TiP Exploiting circulating tumor DNA (ctDNA) to intensif..:

Conca, V. ; Vetere, G. ; Moretto, R....
Annals of Oncology. 35 (2024) - p. S70 , 2024

Link: https://doi.org/10.1016/..

4

Waiting for the "liquid revolution" in the adjuvant treatme..:

Conca, V. ; Ciracì, P. ; Boccaccio, C....
Cancer Treatment Reviews. 126 (2024) - p. 102735 , 2024

Link: https://doi.org/10.1016/..

5

112P The presence of liver metastases does not predict resi..:

Carullo, M. ; Antoniotti, C. ; Rossini, D....
Annals of Oncology. 35 (2024) - p. S52 , 2024

Link: https://doi.org/10.1016/..

6

Cetuximab as third‐line rechallenge plus either irinotecan ..:

Martini, G. ; Ciardiello, D. ; Famiglietti, V....
Cancer Medicine. 12 (2023) 8 - p. 9392-9400 , 2023

Link: https://doi.org/10.1002/..

7

Bone metastases are associated with worse prognosis in pati..:

Dell'Aquila, E. ; Rossini, D. ; Fulgenzi, C.A.M....
ESMO Open. 7 (2022) 6 - p. 100606 , 2022

Link: https://doi.org/10.1016/..

8

Impact of age and gender on the efficacy and safety of upfr..:

Raimondi, A. ; Fucà, G. ; Leone, A.G....
ESMO Open. 6 (2021) 5 - p. 100246 , 2021

Link: https://doi.org/10.1016/..

9

Prognostic and predictive impact of consensus molecular sub..:

Borelli, B. ; Fontana, E. ; Giordano, M....
ESMO Open. 6 (2021) 2 - p. 100073 , 2021

Link: https://doi.org/10.1016/..

10

Variant alleles in factor V, prothrombin, plasminogen activ..:

Falvella, F S ; Cremolini, C ; Miceli, R...
The Pharmacogenomics Journal. 17 (2016) 4 - p. 331-336 , 2016

Link: https://doi.org/10.1038/..

11

416 Variant Alleles in Factor V Leiden (FVL), Prothrombin, ..:

Falvella, F.S. ; Cremolini, C. ; Miceli, R....
European Journal of Cancer. 51 (2015) - p. S83-S84 , 2015

Link: https://doi.org/10.1016/..

12

2190 Discovery of new molecular subtypes of non-hypermutate..:

Pietrantonio, F. ; Perrone, F. ; Cremolini, C....
European Journal of Cancer. 51 (2015) - p. S396-S397 , 2015

Link: https://doi.org/10.1016/..

13

FOLFOXIRI plus bevacizumab as first-line treatment in BRAF ..:

Loupakis, F. ; Cremolini, C. ; Salvatore, L....
European Journal of Cancer. 50 (2014) 1 - p. 57-63 , 2014

Link: https://doi.org/10.1016/..

14

A826 DOES INTRAPLEURAL LIDOCAIKE INFUSION DECREASE PATIENT ..:

Raffin, L. ; Antoniotti, C. ; Sperandio, H...
Anesthesiology. 73 (1990) 3A - p. NA-NA , 1990

Link: https://doi.org/10.1097/..

15

Is There an Optimal Time for Assessing Inpatient Satisfacti..:

C. Antoniotti ; Sapin, C. ; J. Labarere...
Quality of Life Research. 11 (2002) 7 - p. 668 ff. , 2002

Link: https://www.jstor.org/st..